https://www.selleckchem.com/pr....oducts/9-cis-retinoi
The summary RR was 10.63% (95% confidence interval (CI) 5.36-15.89%). The summary disease control rate (DCR) was 28.11% (95% CI 24.60-31.63%). Summary progression-free survival (PFS) was 1.59 months (95% CI 1.24-1.94 months). Summary overall survival (OS) was 5.72 months (95% CI 0-12.19 months). A subset of patients derived long-term benefits as seen in other cancer locations. The adverse effect rate was low and consistent with that in other disease locations. Low efficacy of immune checkpoint inhibitors as a class in gastri
Like
Comment
Share
